Coloplast A/S (Coloplast) is a Denmark-based company engaged in the development, marketing and sale of intimate healthcare products and services. Its operations are structured into four business areas: Ostomy Care, Continence Care, and Wound & Skin Care. The company supplies the products to hospitals, institutions, wholesalers and pharmacies.
Coloplast commits to reducing its operational environmental impacts and raw material impacts through the implementation of efficiency upgrades and utilization of materials with lower emissions profiles for itself and its suppliers. Additionally, the company certifies all sites to the ISO 14001 environmental management system international standard. Coloplast also has a firm foothold in its product quality management. For example, the company complies with the European Union’s REACH chemical safety directive, certifies all sites to ISO 9001 and 13485 quality standards and audits suppliers to assure compliance with its policies. In addition, Coloplast recently created a phthalate reduction target to further mitigate potential quality risks. Lastly, the company demonstrates dedication to ethical marketing and business practices, conducting regular trainings and auditing to monitor compliance. Notably, Coloplast’s corruption policy includes an explicit ban of facilitation payments and offers whistleblower protection to those who observe and speak out against any infractions. The company is also a signatory to the UN Global Compact.
Although Coloplast cites many goals across its key performance indicators, it fails to set quantitative targets for most, limiting the ability of stakeholders to track the company’s performance. In addition, the company lacks a few best practices in the area of human capital management, including stock ownership plans, health and life insurance, and a formal talent development program.
Industry: Health Care
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.